NAMS icon

NewAmsterdam Pharma
NAMS

Overview Fund Activity

29 hedge funds and large institutions have $581M invested in NewAmsterdam Pharma in 2023 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 13 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
29
Holders Change
+10
Holders Change %
+52.63%
% of All Funds
0.46%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
11
Increased
13
Reduced
1
Closed
1
Calls
$3.44M
Puts
–
Net Calls
+$3.44M
Net Calls Change
-$397K

Top Buyers

1
RCM
1
RA Capital Management
Massachusetts
$107M
2
Viking Global Investors
2
Viking Global Investors
Connecticut
$77.6M
3
BCLSI
3
Bain Capital Life Sciences Investors
Massachusetts
$125M
4
FLSM
4
Frazier Life Sciences Management
California
$129M
5
Adage Capital Partners
5
Adage Capital Partners
Massachusetts
$14.3M

Top Sellers

1
JPMorgan Chase & Co
1
JPMorgan Chase & Co
New York
$136K
2
WAM
2
Wolverine Asset Management
Illinois
$0
Name Holding Trade Value Shares
Change 		Shares
Change %
Wells Fargo
26
Wells Fargo
California
$3.57K +$3.57K +300 New
UBS Group
27
UBS Group
Switzerland
$2.18K +$2.18K +183 New
AWM
28
Atticus Wealth Management
Florida
$1.97K – – –
DCM
29
Dupont Capital Management
Delaware
$12 – – –
WAM
30
Wolverine Asset Management
Illinois
– -$63.9K -4,819 Closed
1
2